I want to start working with NAMs
The Challenge
The demand for ethical, predictive, and cost-efficient alternatives to mammalian testing is growing across industries.
Yet many researchers and innovators face barriers: lack of accessible technologies, uncertainty around regulatory acceptance, and limited reproducibility of current in vitro systems.
This creates a gap between scientific ambition and the practical implementation of NAMs (New Approach Methodologies).
Key trends
Regulatory agencies such as REACH in the EU emphasize the growing demand for chemical safety testing, while the DTSC reports that toxicological studies remain inadequate for many high-production volume chemicals.
FDA is actively promoting a new non-animal safety assessment framework, driving the adoption of New Approach Methodologies (NAMs).
Over 70% of consumers express trust and preference for products developed with animal-free testing methods.
There is a unique chance to lead the transition shift towards non-animal models, and shape global guidelines, building credibility with consumers and collaborators while reducing costs and timelines.
By adopting a multi-model approach that leverages the broad range of translational NAMs, innovators can de-risk discovery, accelerate validation, and differentiate themselves as pioneers in ethical science.
Making NAMs Accessible to Every Industry — from Discovery to Development
Ethically Sound in vivo Biology
Our platform uses C. elegans, a non-sentient transparent model widely accepted as a NAMs tool to generate high-content in vivo data aligned with The 3Rs Principle.
It offers a powerful, versatile approach for early toxicity testing and mechanistic insights into gene regulation, biochemical pathways, and the effects of pollutants, chemicals, and nanomaterials.
Automated and Accessible Technology
Whether you prefer to run studies with our team or within your own facilities, we make NAMs accessible.
Through the SydLab™ One platform, you can choose between a full-service CRO project or installing the platform on-site.
Our easy-to-use system empowers any team — even without prior model organism experience — to generate reproducible, decision-grade data with confidence.
Translational Insights
Our assays deliver multi-phenotypic, quantitative outputs, from healthspan and lifespan to stress resistance, NOAEL, and biological age. These datasets provide evidence and support product claims across industries.
Introduce in vivo NAMs in your workflow
Nagi™ C-Age
High-throughput in vivo measurement of lifespan and motility.
Multidimensional insights in a single assay.
Nagi™ B-Age
AI-powered in vivo biological age and healthspan measurement to fast-track your innovation in just 10 days.
Dissect the mechanism of action among 5 vital traits.
Nagi™ DART
High-throughput in vivo Developmental and Reproductive Toxicity assay.
Multidimensional insights in just 5 days.
Recent Projects
With Nagi Bioscience, you gain:
A fast entry point into NAMs
Begin generating in vivo-level insights without the cost or ethical burden of animal studies.
Rapid data generation
Obtain Biological Age metrics in just 10 days and lifespan outcomes in ~20 days.
Scalable capacity
Screen compounds, supporting both exploratory and confirmatory studies.
Regulatory alignment
Build strong scientific evidence that strengthens submissions to regulatory authorities for starting vertebrate studies.
Market differentiation
Position yourself as a leader in innovation and ethical science, backed by robust data.
From first-time adopters to experienced research groups, we make it simple to start working with NAMs, and to pioneer the future of discovery with confidence.
“We had a highly positive experience with Nagi’s services. Their innovative assays provided a reliable alternative to mouse studies by leveraging the short lifespan of C. elegans and the high conservation of our target from worms to human.“
Article: The C. elegans Model in Toxicity Testing
“These cutting-edge technologies can potentially reduce or replace the use of mammals for toxicity testing,”
“Their high-throughput approach provided clear, quantifiable insights into the lifespan and functional effects of our lead combinations— critical data that helped de-risk and prioritize our therapeutic strategy.“